Pathotropic nanoparticles for cancer gene therapy
Rexin-G™ IV: Three-year clinical experience

ERLINDA M. GORDON5, FRANCISCO F. LOPEZ1,2, GERARDO H. CORNELIO1,3, CONRADO C. LORENZO III1,2, JOHN P. LEVY5, REBECCA A. REED5, LIQIONG LIU5, HOWARD W. BRUCKNER4 and FREDERICK L. HALL5

1Departments of Internal Medicine/Medical Oncology, Asian Hospital and Medical Center; 2Makati Medical Center; 3University of the Philippines, Manila, Philippines; 4Department of Medical Oncology, Lutheran Medical Center, Brooklyn, NY 11220; 5Epeius Biotechnologies Corporation, San Marino, CA 91108, USA

Received July 3, 2006; Accepted August 11, 2006

Abstract. Metastatic cancer is a life-threatening illness with a predictably fatal outcome, thereby representing a major unmet medical need. In 2003, Rexin-G™ became the world’s first targeted injectable vector approved for clinical trials in the treatment of intractable metastatic disease. Uniquely suited, by design, to function within the context of the human circulatory system, Rexin-G is a pathotropic (disease-seeking) gene delivery system bearing a designer killer gene; in essence, a targeted nanoparticle that seeks out and selectively accumulates in metastatic sites upon intravenous infusion. The targeted delivery of the cytocidal gene to primary tumors and metastatic foci, in effective local concentrations, compels both cancer cells and tumor-associated neovasculature to self-destruct, without causing untoward collateral damage to non-target organs. In this study: i) we report the results of three distinctive clinical studies which demonstrate the initial proofs of concept, safety, and efficacy of Rexin-G when used as a single agent for advanced or metastatic cancer, ii) we introduce the quantitative foundations of an innovative personalized treatment regimen, designated the ‘Calculus of Parity’, based on a patient’s calculated tumor burden, iii) we propose a refinement of surrogate end-points commonly used for defining success in cancer therapy, and iv) we map out a strategic plan for the accelerated approval of Rexin-G based on the oncologic Threshold of Credibility paradigm being developed by the Food and Drug Administration.

Introduction

Advanced or metastatic cancer is generally associated with a fatal outcome, which eludes the impact of conventional radiation and chemotherapy. Therefore, novel and more-effective therapeutic approaches are urgently needed to address this problem, which constitutes a major unmet medical need. For pancreatic cancer, the fourth leading cause of cancer death in the United States, complete surgical resection of the primary tumor offers the only effective treatment (1,2). Unfortunately, curative resection is only possible in 10-15% of patients with pancreatic cancer, and the median survival time is only 6-10 months for patients with locally advanced pancreatic cancer and 3-6 months for metastatic disease, respectively (3,4). Recently, gemcitabine, a deoxycytidine analogue, has been shown to improve the quality-of-life of patients with locally advanced pancreatic cancer and 3-6 months for metastatic disease (4), and with metastatic disease (6); however, the median survival was extended in the latter case by only 1-2 months, as compared to 5-fluorouracil (5-FU). Nonetheless, gemcitabine is now considered the first-line standard of care in treating patients with pancreatic cancer.

Surgical resection is also the primary treatment modality for patients with colorectal cancer, which is the second leading cause of cancer death in the United States. Additional chemotherapy and radiation treatments have helped to reduce the recurrence of colorectal cancer in patients with early-stage disease (7). However, the effect of these treatments on locally advanced tumors has been less satisfactory (8). Currently, the 5-year survival rate for colorectal cancer patients treated with surgical resection is ~90% for stage I, 70% for stage II, 50% for stage III, and <5% for stage IV. While chemotherapy for colon cancer remains a useful palliative option, which may, at times, even extend to down-staging, the majority of patients with colon cancer exhaust the benefits from standard treatment within 18 months. Moreover, there appears to be a consensus among leading clinical oncologists that targeted ‘biologic therapies’ hold the greatest promise in terms of future clinical development for both pancreatic and colon cancer.

Of the biologic therapies currently in development as alternatives to traditional chemotherapeutics, angiogenesis inhibitors, cancer immunotherapy, and cancer gene therapy strategies are undergoing active clinical investigations (9-11). Indeed, ~70% of all the initial gene therapy protocols prior to the year 2000 were aimed at treating metastatic cancer (11).
Unfortunately, none of the initial studies employing non-targeted vectors demonstrated a clear clinical benefit, leading to the conclusion that the major problem that has hindered the development and deployment of effective cancer gene therapy is that of inefficient gene delivery to target cells in vivo (9,12-15), a technological problem that at once obviates and precludes many direct gene therapy approaches (10). Thus, genetic medicine at the turn of the century stood poised yet stalled at the threshold of clinical history. In this regard, the development of tumor-targeted Rexin-G represents a quantum step forward in both safety and efficacy in this preferred pathway of developing biologic therapies.

The advent of ‘pathotropic (or disease-seeking) targeting’ introduces a new paradigm in cancer gene therapy - a new vehicle, in terms of medical delivery - and a new technology which ushers modern medicine across this threshold. Uniquely suited, by design, to function within the human vascular system, this targeted delivery system embodied in the molecular structure of Rexin-G directs therapeutic nanoparticles selectively to areas of severe pathology (i.e., pathotropic targeting), which enables preferential gene delivery to significant vascular lesions (16,17), to areas of active tumor-associated angiogenesis, and to metastatic cancer nodules (18,19) with high efficiency in vivo. These targeted, injectable pathotropic nanoparticles, or vectors, incorporate a physiological surveillance function derived from the extracellular matrix-binding domains of von Willebrand (blood coagulation) factor by molecular engineering of the retroviral envelope protein (17). This surveillance function serves to facilitate vector accumulation in tumors and tumor-associated neovasculature wherein certain collagenous proteins are exposed and/or deposited as a result of tumor invasion and tumor-associated angiogenesis (18-22). When injected intravenously, these circulating pathotropic nanoparticles accumulate in metastatic deposits within minutes (19) and enable efficient gene delivery to remote metastatic sites (18,19).

Therefore, by targeting the distinctive histopathology of the tumor microenvironment - rather than the diversity of cancer cells per se - effective vector concentrations at metastatic sites can be optimized, and both the safety and the efficacy of the circulating pathotropic nanoparticles can be increased dramatically. With safety features further enhanced by the inherent properties of the retroviral vector itself, which selectively transduces dividing cells only (23), and the strategic specificity of a modified cell cycle control gene, which limits its function to tumoricidal and anti-angiogenic activities (19), the preclinical and clinical performance of these pathotropic nanoparticles establishes a critical proof-of-principle: the potential for systemic delivery of surveillant genetic medicine in the treatment of primary, metastatic, and occult cancers. As the unique ability of Rexin-G, with its pathotropic gene delivery system, is formally demonstrated to reach and safely impact metastatic disease in the clinic, it continues to lead the field of targeted genetic medicine as an enabling technology platform.

Materials and methods

Product description (Rexin-G for intravenous use). Rexin-G is a pathotropic (extracellular matrix or ECM-targeted) retroviral-based nanoparticle/gene delivery vector, encoding a dominant negative mutant construct of the human cyclin G1 gene expressed under the control of a hybrid LTR promoter (24). The vector also contains the neomycin resistance gene, which is driven by the SV40 early promoter and is utilized for the determination of vector titer. The Rexin-G targeted injectable vector is produced by transient co-transfection of three separate plasmids in 293T cells (human kidney 293 cells transformed with the SV40 large T antigen) maintained as a fully validated master cell bank. Producer cell growth medium is comprised of a DMEM base supplemented with 4 g per l glucose, 3 g per l sodium bicarbonate, and 10% gamma irradiated fetal bovine serum (Hyclone). The serum was obtained exclusively from USA sources, and has been tested to be free of bovine viruses in compliance with USDA regulations. The production, suspension, and collection of therapeutic nanoparticles are performed in the absence of bovine serum in a final formulation of proprietary medium, which is processed by sequential clarification, filtration and final fill into cryobags using a sterile closed loop system. The resulting C-type retroviral particles, with an average diameter of 100 nm, are devoid of all viral genes, and are fully replication defective. The titers of the clinical lots range from 3x10^7 to 1x10^8 gene transfer units (U)/ml, and each lot is validated for requisite purity and biological potency.

Shipping, storage, preparation, and infusion of Rexin-G. Processed clinical-grade materials in sealed cryobags are stored in a -70±10°C freezer prior to shipment. Each lot of validated and released cryobags containing the Rexin-G vector is shipped on dry ice to the clinical site where the vector is stored in a -70±10°C freezer until used. Fifteen minutes before intravenous infusion, the vector is rapidly thawed in a 37°C water bath and immediately infused or transported on ice in a dedicated tray or cooler to the patient’s room or clinical site for immediate use. Patients receive the infusion of Rexin-G via a peripheral vein or a central IV line. Various dosing regimens were used, as described in clinical studies A, B and C (below); however, a maximum volume of 8 ml/kg/dose is given once a day. Each bag of Rexin-G is infused over 10-30 min at a rate of 4 ml/min.

Clinical studies. Three clinical trials involving seventeen patients were conducted using intravenous infusions of Rexin-G for treating metastatic pancreatic cancer and other solid tumors; these clinical trials are listed in Table I and are referred to as Studies A, B and C.

Clinical Study A includes Phase I/II or single-use protocols investigating intravenous infusions of Rexin-G for locally advanced or metastatic pancreatic cancer following approval by the Philippine Bureau of Food and Drugs (BFAD) or by the United States Food Drug Administration (FDA), and the Institutional Review Board or Hospital Ethics Committee (24). The objectives of the study were: i) to determine the safety/toxicity of daily intravenous infusions of Rexin-G, and ii) to assess potential anti-tumor responses to intravenous infusions of Rexin-G. The protocol was designed for patients with an estimated survival time of at least 3 months. After informed consent was obtained, six patients with locally advanced unresectable or metastatic pancreatic cancer...
were treated with repeated infusions of Rexin-G. Five of the six patients had failed standard chemotherapy; three of which completed the intra-patient dose escalation protocol in Manila, Philippines and/or in Brooklyn, NY, USA, as follows: days 1 and 2, 3.8x10e9 U; days 3 and 4, 7.5x10e9 U; days 5 and 6, 1.1x10e10 U; days 7-10, 1.5x10e10 U; rest one week; days 18-27, 1.5x10e10 U. Two patients received 1 additional cycle, and one patient received 7 additional cycles. The sixth patient who presented with unresectable stage IV pancreatic cancer, received combination therapy as a first-line treatment, consisting of 6 days of IV Rexin-G (3.8x10e9 U/day) followed by gemcitabine (1000 mg/m2) weekly for 8 weeks. For Clinical Study A, the Rexin-G preparation had a potency of 3x10e3 U/ml.

Clinical Study B represents an expansion of Clinical Study A. Based on the encouraging results of the initial clinical experiences with Rexin-G, the Phase I/II study was expanded to further determine the safety and potential efficacy of a higher dose of Rexin-G, to extend the clinical indication to all advanced or metastatic solid tumors that are refractory to standard chemotherapy, and to adjust the treatment schedule and protocol to enable outpatient treatment. The objectives of this study were: i) to determine the safety/toxicity of daily intravenous infusions of Rexin-G, and ii) to assess potential anti-tumor responses to intravenous infusions of Rexin-G at a higher dose level. The protocol was designed for patients with an estimated survival time of at least 3 months. After informed consent was obtained, ten patients with metastatic cancer originating from either the ectoderm (melanoma, 1; squamous cell CA of larynx, 1), the mesoderm (leiomyosarcoma, 1) or the endoderm (pancreas, 2; breast, 2; uterus, 1; colon, 2), and one newly diagnosed previously untreated patient with metastatic pancreatic cancer who had refused chemotherapy (total no. of patients, 11), received intravenous Rexin-G as a single agent at a dose of 3.0x10e10 U per day for a total of 20 days, according to the following treatment schedule: days 1-5, 8-12, 15-19, and 22-26; Monday to Friday with weekend rest period. An improved GMP manufacturing and bioprocessing protocol enabled the production of Rexin-G at substantially higher titers, such that the preparations used for Clinical Study B exhibited a vector potency of 7x10e6 U/ml.

Clinical Study C involves a small group of patients who participated in an Expanded Access Program for Rexin-G for all solid tumors, a provisional program which was recently approved by the Philippine BFAD. The innovative protocol was designed to address (i.e., to reduce or eradicate) a given patient’s total tumor burden as quickly, yet, as safely as possible in order to prevent or forestall ‘catch up’ tumor growth, and thereby minimize this confounding parameter. The estimated total dosage to be utilized was determined by an empiric calculation, referred to herein as ‘The Calculus of Parity’ (defined as a method of equality, as in amount, or functional equivalence). The basic formula takes into consideration the overall tumor burden, estimated from imaging studies (1 cm = ~1x10e6 cancer cells), an empiric performance coefficient (φ) or physiological multiplicity of infection (P-MOI, in the terms of virology) for the targeted vector system (the P-MOI for a non-targeted vector system is essentially infinite), and the potency of the clinical-grade formulation (in U/ml). Tumor burden was measured as the sum of the longest diameters of the tumor nodules, in centimeters, multiplied by 1x10e9 and expressed as the total number of cancer cells. An ‘operationally defined’ performance coefficient (φ) or physiological MOI (P-MOI) of 100 for Rexin-G was based on quantitative demonstrations of enhanced transduction efficiency of the targeted gene delivery system documented in a wide variety of preclinical studies, and upon the dose-dependent performance of Rexin-G observed in the crucible of the initial clinical trials. Importantly, the generation of a high-potency Rexin-G product (~1.0x10e9 Units/ml) enabled the administration of calculated optimal doses of Rexin-G to be delivered intravenously without the risk of volume overload. After completion of the first 20 days of Rexin-G infusions, two patients with metastatic pancreatic cancer and one patient with metastatic colon cancer opted (with additional informed consent) to continue to receive intravenous Rexin-G infusions up to a total dose of ~2.5x10e11 U over 6 weeks (one patient) and 16 weeks (two patients), respectively. This provided a Calculus of Parity which roughly paralleled the patients’ estimated tumor burden based on CAT scan or MRI.

**Evaluation of safety and efficacy of Rexin-G.** Adverse events were graded according to the NIH Common Toxicity Criteria (CTCAE version 2 or 3) (25). To evaluate the clinical efficacy of Rexin-G, we took into consideration the general cytotoxic and anti-angiogenic activities of the agent (18,19), as well as the dynamic sequestration of the pathotropic nanoparticles into metastatic lesions (19) that would affect the biodistribution and bioavailability of the targeted nanoparticles during the course of the treatment. Since the vector will accumulate more readily in certain cancerous lesions, depending on the degree of tumor invasiveness and angiogenesis, it is not expected to be distributed evenly to the rest of the tumor nodules, particularly in patients with large tumor burdens. This would predictably induce a mixed tumor response wherein some tumors may decrease in size while other tumor nodules may become bigger and/or new lesions may appear. Thereafter, with the normalization or decline of the overall tumor burden, the pathotropic surveillance function would distribute the circulating nanoparticles somewhat more uniformly. Additionally, the treated lesions may initially become larger in size due to the inflammatory reactions or cystic changes induced by the necrotic tumor. Therefore, two additional measures were used in the evaluation of objective tumor responses to Rexin-G treatment, aside from the standard
Response Evaluation Criteria in Solid Tumors (RECIST; 26):
i) O'Reilly's et al formula for estimation of tumor volume:
\[ L \times W^2 \times 0.52 \] (27), and ii) the induction of necrosis or cystic changes in tumors during the treatment period. Thus, a decrease in the tumor volume of a target lesion of ≥30%, or the induction of necrosis or cystic changes within the tumor were considered partial responses (PR) or positive effects of treatment.

Statistical analysis. For Clinical Study A, the one-sided exact test was used to determine the significance of differences between the PRs of patients treated with Rexin-G and historical controls with an expected 5% PR.

Results

Clinical Study A. This initial Phase I/II study examines the safety and potential efficacy of an intra-patient dose escalation protocol. As shown in Table II, partial responses (PR) of varying degrees were noted in five out of six patients treated with Rexin-G while stable disease was observed in the remaining patient. Three of six (50%) patients had a ≥30% decrease in tumor size by RECIST or by tumor volume measurement, and two of six (33%) patients had necrosis of either the primary tumor or metastatic nodules by biopsy and/or by follow-up MR/ICAT scan. Further analysis of one particular patient (A3), in whom 6 of 8 liver tumor nodules disappeared by CT scan, was facilitated by means of a liver biopsy, which revealed an increased incidence of apoptosis, necrosis, and fibrosis within the tumor nodules similar to that observed in preclinical studies (18,19), along with the observation of numerous tumor infiltrating lymphocytes in the residual liver tumors of the biopsied liver (Figs. 1-3). The presence of immunoreactive T and B lymphocytes infiltrating the residual liver tumors (Fig. 3) indicates that Rexin-G does not suppress local immune responses. Progression-free survival was greater than 3 months in four of six (67%) patients. Median survival after Rexin-G treatment in chemotherapy-resistant patients was 10 months, and median survival after diagnosis was 25 months. In contrast, the reported median survival of patients with pancreatic cancer who received either gemcitabine or 5-FU (standard treatments) as a first-line drug was 5.65 and 4.41 months after diagnosis, respectively (28). Using the one-sided exact test, the significance level of partial responses in Rexin-G-treated patients was <0.025 when compared to the PR rates of historical controls. These initial findings, albeit documented in a relatively small number of patients, are sufficient to indicate that Rexin-G is clinically effective, even in modest doses, is clearly superior to no medical treatment, and may be superior to gemcitabine when used as a single agent for the treatment of patients with advanced or metastatic pancreatic cancer.

All six patients tolerated the Rexin-G infusions well with no associated nausea or vomiting, diarrhea, mucositis, hair loss, or neuropathy. Three of six (50%) patients had symptomatic relief of pain. There was no significant alteration in hemodynamic function, bone marrow suppression, liver,
kidney or any organ dysfunction that was related to the investigational agent. The only adverse events that were attributed as definitely related to the investigational agent were generalized rash and urticaria in two of six patients (grade 1-2), and those attributed as possibly related were chills and fever in two of six patients (grade I). The limited number of treatment-emergent adverse events observed in this study suggests that Rexin-G administered intravenously at these escalating doses is a relatively safe therapy.

Clinical Study B. This study extends the initial Phase I/II pancreatic cancer protocols with dose intensification and expanded clinical application to all solid tumors. As shown in Table III, partial responses of varying degrees of either the primary tumor or the metastatic nodules were noted in seven of eleven (64%) patients. Five of eleven (45%) patients developed necrosis and apoptosis of the primary tumors and/or metastatic nodules by either biopsy or CT scan, and five of eleven (45%) patients had >30% reduction in the size of the primary tumor or metastatic nodules by RECIST or tumor volume measurement. Two of eleven patients had stable disease, one patient with massive tumor burden had a mixed tumor response and one patient with a large tumor burden (~50 liver nodules) had progressive disease.

Progressive reduction of cancerous lymph nodes with repeated infusions of Rexin-G was consistently observed in patients with pancreatic cancer, and again in patients with
uterine cancer, colon cancer, breast cancer and malignant melanoma, which is remarkable and meaningful in terms of understanding the pertinent pharmacodynamics. While it is well known that sentinel lymph node(s), the first lymph node(s) to which cancer is likely to spread from a primary tumor, are of considerable importance to our understanding...
of the pathogenesis, diagnosis, and prospective treatment of metastatic disease, the conspicuous penetrance of Rexin-G into both regional and distant lymph nodes is both striking and auspicious (Tables II and III). The clinical significance of the finding that the pathotropic nanoparticles in Rexin-G retain their bioactivity as they circulate throughout the body, not only accumulating in primary and metastatic lesions but also draining into lymph nodes with therapeutic impact, cannot be overstated. As shown in Fig. 4, a surgical biopsy of a cancerous lymph node from the inguinal region of a patient with malignant melanoma showed substantial necrosis (Fig. 4A), large areas of overt apoptosis, (Fig. 4B), and zones wherein hemosiderin-laden macrophages (Fig. 4C) are evacuating tumor debris. Moreover, immunohistochemical staining revealed significant mononuclear infiltrations with immunoreactive CD35+ dendritic cells, (E) CD68+ macrophages and (F) CD8+ killer T cells.

In another patient with squamous cell carcinoma of the larynx, a dramatic re-opening of the upper airway was documented by neck MRI (Fig. 5), which correlated with the patient regaining her voice. Progression-free survival ranged from 1 to >5 months. Median survival time was >6 months.
from the start of Rexin-G treatment, and >24 months from diagnosis. Eight of eleven (72%) patients lived/are alive >6-13 months after treatment with Rexin-G. Taken together, Rexin-G appears to have single-agent activity in a broad spectrum of resistant tumor types. Further, it was noted that sustained therapeutic benefit was observed in the majority of the patients despite the brevity of the treatment.

All eleven patients tolerated the vector infusions well with no associated nausea or vomiting, diarrhea, mucositis, hair loss or neuropathy. Eight of eleven (73%) had symptomatic relief of pain, bloating, throbbing, hoarseness, and fatigue. There was no significant alteration in hemodynamic function, bone marrow suppression, liver, kidney or any organ dysfunction that was related to the investigational agent. The absence of treatment-related adverse events further suggests that, even in increased vector doses, Rexin-G is a relatively safe therapy. At this point, the absence of dose limiting toxicity, combined with compelling indications of single-agent efficacy in a variety of different tumor types and the recent availability of higher potency formulations of Rexin-G encouraged the advancement and regulatory approval of clinical trials designed to focus on increased clinical efficacy and the optimization of treatment protocols.

Clinical Study C. This study represents the initial report of clinical experience in an Expanded Access Program for Rexin-G for treating all solid tumors, introducing an innovative personalized dose-dense regimen referred to as the Calculus of Parity. In this preliminary yet important interim analysis, dramatic responses were noted in all three patients, each with an extensive tumor burden. In one patient (C1), the Calculus of Parity (or functional equivalence) approximated a cumulative dosage that led to liquefaction necrosis and cystic conversion of the unresectable pancreatic tumor and either cystic conversion or disappearance of all metastatic liver nodules on follow-up MRI (Fig. 6). Aspiration of one cystic tumor nodule was negative for malignant cells. In the second patient (C2), suffering from stage IV colon cancer, a cumulative dosage approaching the predetermined Calculus of Parity was effective in reducing the bulk of the metastatic disease: 84% necrosis observed in the liver tumor nodules was documented by image analysis. In the third patient (C3), a significant decrease in the primary pancreatic tumor and in the number (from 28 to 12 lung nodules) and the size of pulmonary nodules were noted by CT scan. Progression-free survival and overall survival was >6 months after Rexin-G treatment in two patients. These findings provide preliminary evidence to support the hypothesis that the Calculus of Parity may be used to determine the total cumulative dose of Rexin-G that would be needed to address a given patient's tumor burden, and thereby comprise an optimal induction regimen.

All three patients tolerated the vector infusions well with no associated nausea or vomiting, diarrhea, mucositis, hair loss or neuropathy. There were no acute alterations in hemodynamic function, bone marrow suppression, liver, kidney or any organ dysfunction that was related to the investigational agent. Two patients did develop anemia requiring red cell transfusion (grade 3), which was attributed as possibly related to subsequent bleeding into the necrotic tumors. One patient developed sporadic episodes of thrombocytopenia (grade 1-2) which was attributed as possibly related to the investigational agent. One patient died of acute fulminant staph epidermidis sepsis 3 months after treatment, which was not attributed to the investigational agent. The results of this patient's autopsy showed almost complete necrosis of the residual pancreatic tumor, and 75-95% necrosis of the metastatic tumors remaining in the liver and abdominal mesentery, with normal histology recorded in the bone marrow, heart, and brain. The lack of systemic toxicity associated with Rexin-G administration underscores the potential advantages of Rexin-G over standard chemotherapy in terms of efficacy in managing metastatic cancer, as well as other quality-of-life measures. In each case, the extent of the overall tumor destruction was impressive. The demonstration that a dose-dense regimen of Rexin-G, specifically tailored to overcome a patient's tumor burden, is capable of achieving...
these levels of efficacy underscores the need to further refine the Calculus of Parity, to define the optimal rate(s) of tumor eradication, and to discern the optimal supportive care for a patient undergoing post-tumoricidal wound healing.

Discussion

Targeted biologic therapies in general, and targeted gene delivery systems, in particular, are expected to change the way cancer therapy will be administered, evaluated, and regulated in the future. The advent of pathotropic targeting, a disease-seeking technology platform embodied in the intricate design of Rexin-G has ushered genetic medicine, as well as medical nanotechnology, across the threshold of history, with unprecedented demonstrations of single-agent efficacy. Although the total numbers of patients treated to date with this pioneering genetic medicine are still quite small, the high percentage of objective clinical responses enables tentative conclusions to be made. Critical analysis of the initial Phase I/II studies cautiously evaluated general safety considerations, while gradually escalating doses (intra-patient) to a point at which efficacy was observed in pancreatic cancer (24). Expanding the dose-escalation protocols to include higher cumulative doses, as well as additional tumor types provided additional evidence of the overall safety and efficacy of the treatment. Rapid and systematic sharing of comprehensive information and records with all regulatory authorities in both the USA and the Philippines facilitated the critical analysis and expedited the advancement of the clinical trials. Based on the initial demonstrations of safety and efficacy of Rexin-G in pancreatic cancer, the United States FDA granted Orphan Drug status to Rexin-G as an effective treatment for pancreatic cancer, while the Philippine BFAD approved limited commercialization of Rexin-G through an Expanded Access program for all solid tumors considered resistant to standard chemotherapy.

The recent availability of a very high-potency preparation (1-5x10^9 U/ml) of Rexin-G has overcome the problems of infusion volume and dosing limitations to a remarkable extent, and enabled the advancement of the investigations to include strategic dose-dense regimens defined as the Calculus of Parity. Taken as a whole, the ongoing clinical studies presented in this report serve to validate the clinical utility of pathotropic targeting, the relative safety of intravenous Rexin-G, and the dose-dependent efficacy of this targeted genetic medicine in the treatment of incurable metastatic cancer. Moreover, as analysis of each clinical experience benefits the next, these studies provide new insights regarding strategic dosing, patient monitoring, critical evaluation of tumor responses, and a general appreciation of the need for expedited clinical development. After all, it is apparent from our studies that Rexin-G positively impacts overall survival and the quality-of-life of patients with advanced metastatic cancer.

Tumor kinetics and the ‘Calculus of Parity’ for personalized cancer medicine. In cancer therapy, a critical factor influencing the efficacy of an investigational agent is the extent of the tumor burden. Often, the margin of safety of a test drug is too narrow because dose-limiting toxicity is reached prior to gaining tumor control. Thus, the development of a cancer drug that can actually address the tumor burden without eliciting dose-limiting side effects or organ damage represents a significant milestone and advancement in cancer treatment. Another important problem is the natural kinetics of cancer growth, which requires an appropriate kinetic solution. Historic models of tumor growth are now considered overly simplistic (29,30), yet these simplistic models greatly influenced the development of standards of cancer treatment that are still enforced today; including the use of drugs in combination, and in equally spaced cycles of equal intensity. While the prediction that tumor shrinkage is correlated with improved prognosis is certainly true, the prediction that giving conventional drugs long enough would lead to tumor eradication has been proved false (31). Appreciation of a more complex kinetics, as described by Benjamin Gompertz and formalized as the Norton-Simon model, takes into account the dynamics of metastasis and the quantitative relationship between tumor burden and metastatic potential in its predictions. Thus, the concept of dose-dense chemotherapies emerged, which emphasized the optimal doses of drugs that cause regression of the tumor over shorter time intervals and favored sequential rather than combinatorial approaches (31,32). Subsequently, a number of clinical trials provided supportive evidence that giving drugs more densely made a significant difference in terms of optimizing cancer cell kill.

The introduction of pathotropic nanoparticles for targeted gene delivery enables a new and quantitative approach to treating metastatic cancer in a unique and strategic manner. Developed conceptually by Gordon and Hall, the Calculus of Parity described herein represents an emergent paradigm that seeks to meet and to match a given tumor burden in a highly compressed period of time; in other words, a dose-dense induction regimen based quantitatively on best estimates of total tumor burden. The Calculus of Parity assumes the following from the outset: i) that the therapeutic agent (in this case Rexin-G) is adequately targeted such that physiological barriers including dilution, turbulence, flow, diffusion barriers, filtration, inactivation, and clearance are sufficiently counteracted such that a physiological performance coefficient (P-MOI) can be calculated; ii) that the agent is effective at levels that do not confer restrictive dose-limiting toxicities; and iii) that the agent is available in sufficiently high concentrations to allow for intravenous administration of the personalized doses without inducing volume overload. To calculate the optimal daily dosage of Rexin-G, the following factors were taken into consideration: i) the total tumor burden based on radiologic imaging studies; ii) the physiological performance coefficient (P-MOI) of the system, which specifies the multiplicity of inducible gene transfer units needed per target cancer cell; and iii) the precise potency of the vector in terms of gene transfer units (U) per ml. The Calculus of Parity predicts that tumor control can be achieved if the dose of the targeted vector administered is equivalent to the emergent tumor burden; yet the total dosage should be administered in as short a period of time as considered safely possible, in order to prevent catch-up tumor growth while allowing time for the reticuloendothelial system to eliminate the resulting tumor debris (18). Our preliminary clinical experience with this calculus (see Study C) is limited to three patients, each with relatively large tumor burdens; however, the dramatic responses...
observed in two patients who failed standard chemotherapy and in one patient who refused standard chemotherapy (100% response rate) underscores both the potential utility and the urgent need for further studies of the quantitative approach.

To RECIST or not to RECIST: The advent of targeted therapies, including targeted gene therapy, is also changing the way tumor responses to a cancer drug are being evaluated. The guiding principle in cancer therapy has been that the therapeutic benefit gained from a prospective chemotherapeutic agent must outweigh the risk of serious or fatal systemic toxicity induced by the drug candidate. To this end, the Response Evaluation Criteria in Solid Tumors (RECIST) was developed by the National Cancer Institute (NCI), Bethesda, MD, USA, and has been employed by most, if not all, academic institutions as the universal standard for tumor response evaluations (27). Specifically, an objective tumor response (OTR) has, until recently, been considered the golden standard of success in evaluating cancer therapy for solid tumors. An OTR consists of at least a 30% reduction in the size of target lesions and/or complete disappearance of metastatic foci or non-target lesions. However, many biologic response modifiers of cancer are, in fact, not associated with tumor shrinkage, but have been shown to prolong progression-free survival (PFS), and overall survival (OS) (33). Hence, the response to effective biologic agents is often physiologic and RECIST may no longer be the appropriate standard for evaluation of tumor response to biologic therapies. Thus, alternative surrogate end-points such as measurements of tumor density (an index of necrosis), blood flow and glucose utilization in tumors, and other refinements of imaging methods used to evaluate the mechanisms of tumor response are required.

Understanding the disease process, as well as the intended mechanisms of action of the proposed intervention is, therefore, critical in predicting the effect of the treatment on a given clinical end-point. In the case of tumor responses to Rexin-G, wherein the primary mechanism of action is the induction of apoptosis in proliferative tumor cells and attendant angiogenic vasculature, necrosis and cystic changes within the tumor often occur. This is due to the targeted disruption of a tumor’s blood supply which starves the tumor, resulting in subsequent necrosis within the tumor. In tumors of Rexin-G-treated patients, wherein apoptosis is a predominant feature, the tumors simply shrink and disappear in follow-up imaging studies. However, in tumors wherein necrosis is a prominent feature, the size of the tumors may actually become larger after Rexin-G treatment, due to the inflammatory reaction evoked by the necrotic tumor and cystic conversion of the tumor. In this case, an increase in the size of tumor nodules on CT scan, PET scan or MRI does not necessarily indicate disease progression. Therefore, additional concomitant evaluations that reflect the histological quality of the treated tumors are needed to more accurately determine the extent of necrosis or cystic changes induced by Rexin-G treatment.

The tumor responses observed in Clinical Study C further strengthen these arguments. In the two patients who received an optimal dose of Rexin-G based on the ‘Calculus of Parity’, an aggregate increase in the size of the tumor nodules was noted. However, examination of the nature of the lesions showed >95% liquefaction necrosis in all the tumor nodules of Patient C1 by MRI, while 84% necrosis within the tumor nodules of Patient C2 was noted by PET scan. In Patient C3, there was a significant decrease in both the number and size of the primary tumor and metastatic foci two weeks after completion of Rexin-G therapy, indicating that apoptosis was a prominent feature in Patient C3’s tumor response to Rexin-G. Thus, careful attention to the quality of the treated tumors in Patients C1 and C2 resulted in a more accurate evaluation of tumor response which influenced the decision to continue, rather than discontinue, treatment with Rexin-G. Conversely, failure to consider the necrotic and cystic changes within the tumor would have resulted in an erroneous diagnosis of progressive disease and an imprecise conclusion of lack of Rexin-G activity in Patient C1’s and C2’s tumors. In summary, the understanding of events that precede and accompany tumor eradication by Rexin-G, i.e., apoptosis, necrosis, tumor lymphocytic infiltration, cystic changes, and reactive fibrosis and stroma formation, first seen in preclinical studies (18,19,34) and now documented in clinical trials, indicate that the historical RECIST criteria may be inadequate at best and, at times, misleading. Finally, while it would be desirable to deliver Rexin-G much earlier in the course of the disease process, well before the metastatic tumor burden has reached such massive proportions, it is important to note that these determinations of clinical efficacy were performed in the most resistant types of cancer.

The oncologic ‘threshold of credibility’ paradigm developed by the FDA for accelerated approval of investigational cancer agents. Finally, the development and advancement of targeted therapies, including pathotropic nanoparticle-mediated gene delivery systems, will hopefully impact the way these agents are regulated and approved by the United States FDA and other regulatory agencies worldwide (35,36). In recent years, the FDA approved certain small molecule agents and biologic response modifiers for the treatment of advanced cancer based on surrogate end-points that showed a meaningful clinical benefit, such as enhanced quality-of-life, longer progression-free survival, and overall survival (28,33). According to the FDA’s ‘The Pink Sheet’ for prescription pharmaceuticals and biotechnology products (35), oncologic approval could be based on surpassing a threshold of credibility rather than demonstrating statistical benefit. The threshold of credibility would be achieved when relatively small numbers (20-30 patients) demonstrate a meaningful clinical effect in a single arm confirmatory clinical trial. The oncologic threshold of credibility paradigm was developed in an attempt to streamline the approval process for highly active entities by reducing the size of the trials and the complexity of statistical analysis. This approach is particularly effective in allowing seminal clinical trials to expand the scope of potential applications, as in the case of Rexin-G for all solid tumors, while advancing the investigational agent in an orderly manner.

Based on preliminary yet consistent observations of overall safety and efficacy in the management of incurable metastatic disease, Rexin-G merits expedited evaluation. Moving forward with the clinical development of Rexin-G as a potentially important treatment for metastatic pancreatic cancer, the present strategy is to conduct a Phase II single arm study in a limited number of patients who have failed standard
chemotherapy. The development plan we have chosen addresses the most difficult clinical problems in cancer therapy, as these tumors are the most resistant and universally recognized refractory tumors. The initial demonstrations of both benefit and safety in these most difficult patients 'raises the bar' for biologic therapy. Based on our recent human experience with Rexin-G, we anticipate that the clinical protocol will be guided by the Calculus of Parity and will consist of a dose-dense induction regimen wherein optimal doses of Rexin-G will be given over a relatively short period of time (4-8 weeks) to be followed by a maintenance regimen based on estimates of residual tumor burden. The efficacy endpoints of the planned Phase II trial would involve a thorough assessment of quality-of-life parameters, measurement of tumor volume and tumor density in target lesions, identification of necrosis, inflammatory infiltrations, and/or cystic changes in tumors, in addition to the standard methods of evaluating tumor responses, including OTR, PFS and OS. As the number of treated patients increases, evaluations will be performed categorically, in each individual tumor type, as well as collectively in aggregate.

In conclusion, we have reported the results of three clinical studies using Rexin-G, a new biologic agent that has been developed for the treatment of metastatic cancer. Based on these studies, the following conclusions are presented: i) the functionality of the gene delivery system is profound, ii) the genetic construct exhibits broad spectrum activity in many resistant tumor types, and iii) the targeted genetic medicine is exceptionally safe. The lack of systemic toxicity, taken together with the reduction of tumor burden and the enhanced quality-of-life experienced by patients receiving Rexin-G infusions, constitute meaningful clinical benefits that underscore the need for the expedited development of Rexin-G for pancreatic cancer and, potentially, for all solid tumors.

Acknowledgements

The authors are grateful to R.N. Evangeline Camunayan, for her assistance in the administration of Rexin-G, Drs Maria Teresita Castillo and Nelson Geraldino, Department of Pathology, Asian Hospital and Medical Center, for histologic examination of pathology specimens, Dr Manuel Madayag, Department of Radiology, Asian Hospital and Medical Center, and Dr Ramon Santos Ocampo, Department of Radiology, Makati Medical Center, Manila Philippines for their radiologic interpretation of the imaging studies, and Ms. Heather Colleen Gordon for her valuable assistance in the preparation of this manuscript. This study was supported by Epeius Biotechnologies Corporation, San Marino, CA 91108, USA.

References